Riskpilot← Back to searchSign inGet full accessSANA PHARMA MANAGEMENT AS
ASActiveOrg 914756324Philip Pedersens Vei 20, 1366 LysakerWholesale of pharmaceutical and medical goods · NACE 4646Est. 20150 employees
Revenue 2024
NOK 0
EBITDA margin
—
-27% vs 2023
Equity ratio
99.1%
Financial strength
Net profit 2024
NOK -118K
-175% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -125K | -27% |
| Net profit | NOK -118K | -175% |
| Total assets | NOK 30,2M | +0% |
| Equity | NOK 30M | +0% |
| Employees | 0 | — |
Legal name
SANA PHARMA MANAGEMENT AS
Org number
914756324
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
7. januar 2015
Share capital
NOK 90 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Investering i andre selskaper samt det som naturlig står i forbindelse med dette.
Address
Philip Pedersens Vei 20, 1366 Lysaker
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −31 | −29 | −58 | −99 | −125 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −31 | −29 | −58 | −99 | −125 |
| Net financials | 0 | 2 | 37 | 56 | 7 |
| Profit before tax | −31 | −27 | −22 | −43 | −118 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −31 | −27 | −22 | −43 | −118 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 19 694 | 30 153 | 30 153 | 30 195 | 30 247 |
| Equity | 19 640 | 30 153 | 30 132 | 30 089 | 29 970 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 55 | 0 | 21 | 106 | 276 |
| Total debt | 55 | 0 | 21 | 106 | 276 |
EBITDA margin
-12545100.0%
This company
15.8%
Market median
-79399467% vs market
20202024
Equity ratio
99.1%
This company
38.2%
Market median
+159% vs market
20202024
Return on equity
-0.4%
This company
18.4%
Market median
-102% vs market
20202024
Net profit margin
-11821300.0%
This company
8.1%
Market median
-145942075% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AK Contact Person | Contact Person | 2015 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Former (2) | ||
| Board of Directors | 2015 – 2021 | |
| Chairman | 2021 – 2023 | |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
SANA PHARMA MANAGEMENT AS 
Sana Pharma Medical AsBoard members of SANA PHARMA MANAGEMENT AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andres Kongsgaard Flaaten | Contact Person | 0 companies |
| Heidi Tveit | Chairman | 0 companies |
| Morten Brennesvik-Jensen | Board of Directors | 0 companies |
| Kenneth Frode Goovaerts Bern | Board of Directors | 0 companies |
| Per Anders Larnholt | Chairman | 0 companies |